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Abstract
Introduction: The proton pump inhibitor empirical trial, besides the analysis of
symptoms, is the main method in the diagnosis of gastro-oesophageal reflux
disease-related chest pain. β-Endorphin acts as an endogenous analgesia system.
The aim of the study was verify whether β-endorphin plasma level is affected
by omeprazole administration and influences the severity of anginal symptoms
and outcome of the “omeprazole test” in patients with coronary artery disease
(CAD) and chest pain of suspected non-cardiac origin. 
Material and methods: Omeprazole was administered to 48 patients with CAD
in a randomized, placebo-controlled, crossover study design. At the beginning
of the study, and again after the 14-day omeprazole and placebo treatment, the
β-endorphin plasma concentration was determined. 
Results: The level of plasma β-endorphin after the administration of omeprazole
was significantly greater than at the start of the study and following the placebo.
Responders to omeprazole had an average lower β-endorphin plasma
concentration than subjects who failed to respond to this therapy. Subjects with
symptoms in class III (according to the Canadian Cardiovascular Society
classification) after omeprazole administration had a greater β-endorphin plasma
level than subjects in class II for anginal symptom severity. 
Conclusions: Fourteen-day therapy with a double omeprazole dose significantly
increases the β-endorphin plasma concentration in patients with CAD. Circulating
β-endorphin does not seem to be involved in the mechanism for the “omeprazole
test” outcome, although an individually different effect on pain threshold cannot
be excluded. 
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Introduction
Chest pain is one of the most common symptoms in health care. The
mean annual prevalence of angina-like retrosternal chest pain of non-202 Arch Med Sci 2, April / 2010
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cardiac origin (non-cardiac chest pain, NCCP) in the
general population is approximately 25% [1, 2]. The
most frequent cause of NCCP is gastro-
oesophageal reflux disease (GORD), which
frequently coexists with coronary artery disease
(CAD) [3]. GORD-related chest pain may be
indistinguishable from ischaemic cardiac pain [1-3].
After excluding its cardiac source, empirical therapy
with a double or triple standard dose of proton
pump inhibitor is recommended as an initial
diagnostic approach [1, 2, 4-6]. The results of our
investigations showed that 14-day therapy with
a double dose of rabeprazole (open-label trial) [3]
or omeprazole (randomized, placebo controlled
cross-over trial) [7] leads to a decrease in the
number of total chest pain episodes and in some
electrocardiographic signs of myocardial ischaemia
in patients with stable angina pectoris and CAD.
The pathomechanism of symptom improvement
after therapy with proton pump inhibitor is mostly
explained by a decrease in oesophageal mucosa
injury, diminished chemo- and mechanoreceptor
stimulation, as well as reduction in secondary motor
reaction with hypertensive contractions of the
circular and longitudinal oesophageal muscles [8,
9]. In about half of patients with CAD, related to
gastric acid secretion inhibition, decrease of
stimulus for the cardio-oesophageal reflex and the
prevention of reflexive reduction in myocardial
perfusion should also be taken into consideration
[3, 7, 10, 11]. Moreover, because of the proven role
of changes in the central and peripheral pain
threshold in pathogenesis of non-cardiac chest pain
[1, 2, 8, 9], mediators of the brain-gut axis might
also have potential importance in the outcome of
empirical therapy with proton pump inhibitor.
Recently, Dickman et al. [12] reported that
acupuncture is more effective than the addition of
a second proton pump inhibitor dose in therapy of
heartburn in patients who failed to respond to
a single dose. Because it is accepted that
acupuncture works through modulation of
endogenous opioids’ release, the results of this
study suggested involvement of the opioid system
in control of GORD-related symptoms. Opioids, as
the “endogenous analgesia system”, play a role in
mechanisms of somatic and visceral pain
perception, affect behavioural processes, such as
learning and memory [13], modulate the pain
threshold and mood state in patients with CAD [14-
19] and duodenal ulcer disease [20], and regulate
blood pressure, through the endorphin/encephalin
balance [13, 21].
Because the relationships between β-endorphin
plasma level and outcome of therapy with proton
pump inhibitor in patients with CAD had not been
studied, we estimated the changes in β-endorphin
plasma level after omeprazole and placebo
administration. The influence of observed changes
in this opioid plasma concentration on angina
symptoms severity was also assessed. 
Material and methods
We studied 48 patients with obstructive CAD,
proven through coronarography: 11 females (23%)
and 37 males (77%), recruited from a cardiology
outpatient clinic. They suffered from stable,
recurrent, angina-like chest pain, but failed to
respond to standard anti-anginal therapy. For this
reason overlapping of its non-cardiac sources was
suspected. The mean age of the study population
was 59.6 ±7.2 years. The remaining demographic
and clinical data of subjects, stratified by gender,
are presented in Table I. All individuals included in
the experiment participated in all phases of the
study and completed it. None discontinued therapy. 
The investigation was performed according to
the double-blind, crossover, randomized, placebo-
controlled design, so patients acted as their own
controls. With all the patients, an interview, physical
examination, blood sampling for biochemical
determination and the treadmill stress test
according to the Bruce protocol (Schiller,
Switzerland) were carried out. After the baseline
examination, each patient was assigned
a consecutive drug kit, according to the sequence
of his or her participation in the investigation. Each
kit consisted of two boxes with 28 identical-looking
capsules containing 20 mg of omeprazole or the
placebo (filling materials without omeprazole like
in capsules with omeprazole). Randomization was
carried out at the stage of preparing the kits. In the
first investigation phase, patients were asked to
take capsules of omeprazole or the placebo for 14
days, and in the second phase patients were
crossed over to the other arm (omeprazole →
placebo or placebo → omeprazole). This treatment
was recommended as being given in addition to
therapy up to that point. The doses of this
medication did not change for the entire period of
the investigation. Moreover, the participants did not
change their smoking and alcohol drinking habits
or lifestyle. Patients were only permitted to take
short-acting alkalis and nitroglycerine. Following
each of the two phases of the investigation, all
study procedures, i.e. the interview, physical
examination, blood sampling and treadmill stress
test, were repeated.
Determination of β-endorphin plasma
concentration 
Blood samples were collected at approximately
7:15 am, after 15 min of rest, into Lavender
Vacutaner tubes containing EDTA, and gently rocked
immediately after collection to ensure anti  -Arch Med Sci 2, April / 2010 203
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coagulation. The samples were then centrifuged for
15 min at 4°C to collect the plasma, which was then
kept at –80°C. β-Endorphin estimations in the
serum were carried out according to the producer’s
instructions by enzyme-linked immunosorbent
assay (ELISA) (MD Biosciences, Zürich, Switzerland).
The test sensitivity was 0.18 pg/ml, intra-assay
variation < 5%, inter-assay variation < 14%. 
Statistical analysis
Statistical analysis was conducted using
a licensed version of the statistical software
STATISTICA PL 5.0 for Windows. The results are
presented as the mean ± standard deviation (SD)
or n, %. The statistical significance of differences
between females and males (Table I) was checked
using unpaired Student’s t-test and Fisher’s exact
test. The effect of respective interventions on the
β-endorphin level was estimated using ANOVA with
three repetitions and the Scheffe post hoc test, so
all subjects acted as their own controls. Rank
Spearman correlations between the β-endorphin
plasma concentration and the values of the
treadmill stress test parameters were tested.
Ethics 
The study protocol was approved by the local
Bioethics Committee of Nicolaus Copernicus
Feature  Mean ± SD or n (%) Females (n = 11, 23%) Males (n = 37, 77%)
Age [years] 59.6 ±7.2 58.8 ±7.3 62.9 ±6.3
Number of anginal symptoms per week 12.9 ±7.9  13.4 ±5.9 12.8 ±8.5
(median = 8;  (median = 12;  (median = 10; 
range = 5-35) range = 6-26) range = 6-50)
Number of patients with anginal  class II – 36 (75%) class II – 9 (82%) class II – 27 (73%)
symptoms severity graded according  class III – 12 (25%) class III – 2 (18%) class III – 10 (27%) 
to CCS classification
Dyslipidaemia  44 (92%) 11 (100%) 33 (89%)
Concentration of total cholesterol [mg/dl] 232.7 ±43.8 202.1 ±41.2 184.7 ±25.0
Concentration of LDL cholesterol [mg/dl] 179.7 ±60.1 121.3 ±36.8 95.3 ±26.6
Concentration of HDL cholesterol [mg/dl] 49.5 ±12.6 49.0 ±12.8 61.2 ±17.6*
Concentration of triglycerides [mg/dl] 234.7 ±111.4 187.1 ±111.5 136.3 ±63.3
Hypertension  24 (51%) 1 (9%) 23 (90%)*
Diabetes mellitus  14 (27%) 4 (36%) 10 (27%)
Smoking 12 (25%) 3 (27%) 9 (24%)
History of myocardial infarction 30 (63%) 6 (54%) 23 (65%)
History of PCI 16 (34%) 3 (27%) 13 (35%)
History of CABG 7 (15%) 2 (18%) 5 (13%)
Ejection fraction in echocardiography [%] 54.3 ±9.2 54.5 ±9.9 54.2 ±7.7
Aspirin administration 47 (98%) 11 (100%) 36 (97%)
β-Blockers administration 44 (92%) 9 (82%) 35 (95%)
Calcium-blockers administration 13 (28%) 3 (27%) 10 (27%)
ACEI administration 39 (81%) 8 (72%) 31 (83%)
Number of nitroglycerine tablets taken  3.9 ±4.3  4.6 ±4.9 3.6 ±4.1
per week (median = 3;  (median =3;  (median =3; 
range 1-20) range = 0-15) range = 0-20)
Long-acting nitrates administration 22 (45%) 6 (55%) 16 (43%)
Statin administration 45 (100%) 11 (100%) 34 (92%)
BMI [kg/m2] 28.3 ±3.7 26.9 ±4.7 28.7 ±3.4
WHR 0.93 ±0.07 0.85 ±0.06 0.96 ±0.06* 
CAD – coronary artery disease, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft, BMI – body mass index, WHR –
waist to hip (circumferences) ratio, ACEI – angiotensin-converting enzyme inhibitor, *p < 0.05 for differences between females and males
Table I. Demographic and clinical data of studied subjects with CAD (n = 48)204 Arch Med Sci 2, April / 2010
University in Toruń and Collegium Medicum in
Bydgoszcz, Poland. All subjects gave their informed
consent prior to the start of enrolment procedures.
All procedures have been conducted in compliance
with the Declaration of Helsinki.
Results
The plasma β-endorphin concentration after 
2-week therapy with omeprazole was significantly
greater than at the beginning of the study and after
the administration of the placebo (Figure 1).
Response to omeprazole, defined as decrease in
chest pain severity after proton pump inhibitor
administration more than by half, had no significant
effect on changes in β-endorphin plasma level
during the investigation (interaction with the study
phase) (Figure 2). However, patients who reported
a greater than 50% reduction in the number of
chest pain episodes (responders) following
treatment with omeprazole (n = 17/48, 35%) had
a significantly lower average β-endorphin plasma
concentration during the whole study period than
the remaining subjects (ANOVA: main effect of
clinical outcome; F = 4.9, p = 0.037) (Figure 3). 
The changes in the β-endorphin plasma level
after omeprazole therapy were related to the
severity of anginal symptoms before the patient’s
involvement in the study, both in one- and in two-
factorial analysis (ANOVA: F = 4.72, p = 0.013)
(Figure 4). Subjects with symptoms in class III,
according to the Canadian Cardiovascular Society
(CCS) classification (n = 12/48), had a significantly
greater plasma level of β-endorphin after 2-week
omeprazole administration than subjects 
(n = 36/48) with class II anginal symptom severity
(1246.3 ±778.0 vs. 643.6 ±525.5 pg/ml, p = 0.004).
The remaining clinical factors, such as
randomization when taking omeprazole in the first
study phase, gender, age, hypertension, diabetes,
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Figure 1. β-Endorphin plasma level at the study
beginning, and after omeprazole and placebo
administration. ANOVA, F = 36.0, p < 0.0001
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Figure 3. The main effect of kind of treatment clinical
outcome on average β-endorphin plasma
concentration during all three study phases. ANOVA,
F = 4.9, p = 0.037
Figure 2. Differences in β-endorphin plasma level at
the study start and after following study phases in
patients who responded or not to the double dose
of omeprazole. “Responders” were defined as
subjects who reported decrease in chest pain
frequency after omeprazole administration by more
than 50%, and “non-responders” were defined as
individuals with less or lack of improvement.
Interaction between study phase and response to
kind of treatment, ANOVA with three repetitions: 
F =2,2,06, p =0.14
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Figure 4. Differences in β-endorphin plasma level in
relation to anginal symptoms severity before the
patient’s involvement in the study. ANOVA with three
repetitions: F = 4.8, p = 0.013
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dyslipidaemia, smoking, alcohol drinking, and the
kind of CAD treatment, had no significant effect on
β-endorphin plasma concentration. We did not find
any statistically significant relationships between
the β-endorphin plasma level and the course of the
treadmill stress test, either at the start of the study
or after therapy with omeprazole or the placebo.
Discussion
In our study we found an enormous increase of
β-endorphin plasma concentration after 14 days’
administration of a double dose of omeprazole
(Figure 1). To our knowledge, this is the first report
showing, in a controlled, crossover manner, an
increase in the β-endorphin plasma level after
omeprazole therapy. In contrast to our results, in
the study by Tonnarini et al. [20], 30-day treatment
with omeprazole did not influence the plasma level
of β-endorphin in patients with duodenal ulcer
disease. However, in other studies, the plasma 
β-endorphin concentration rose in response to
hypoglycaemia, intense physical exercise, surgery,
and psychological stress in patients with heart
failure, as well as during therapy with ketoconazole
and naloxone [14, 22]. Dexamethasone
administration decreases this opioid’s plasma level.
After ketoconazole therapy the β-endorphin level
increases fivefold [14] but, in our study, following
omeprazole it increased on average by 2000 times
and, after the placebo, by more than 100 times.
Because β-endorphins play an endocrine role in
brain-gut axis function [23], among others, as the
endogenous analgesia system, these results might
explain the improvement in anginal symptoms
observed by us in 35% of patients with CAD after
14-day omeprazole administration (“responders”)
[7]. Increase in β-endorphin plasma level after
treatment with omeprazole might also elucidate
the observation made by Sarkar et al. [24] in
patients with chest pain and GORD. They found that
6-week therapy with a proton pump inhibitor
increases the resting oesophageal pain threshold
via a decrease in central sensitization. 
However, in our investigation responders to the
“omeprazole test” had a lower average β-endorphin
plasma concentration than subjects who failed to
respond to it in one-factorial analysis (Figures 2 
and 3). Moreover, the opioid level was higher in
patients with greater severity of angina symptoms
at the beginning of the study and was not related
to the course of the treadmill stress test, including
the time to the appearance of chest pain (angina
threshold). These observations do not corroborate
the above-mentioned hypotheses. They are also not
consistent with the results of Tonnarini et al. [20],
Falcone et al. [15], and Sadith et al. [18, 19]. The first
showed a significantly higher β-endorphin plasma
level in patients with an asymptomatic active
duodenal ulcer than in subjects with a painful
course of disease [20]. The second found a higher
plasma level of β-endorphin in asymptomatic
patients with silent ischaemia during exercise stress
test than in subjects with anginal symptoms. The
third observed that β-endorphin infusion decreased
adenosine-provoked chest pain in male patients
with CAD, whereas naloxone, an opioid receptor
antagonist, induced the opposite effect [18, 19].
Jarmukli et al. [14], although they showed that an
increased  β-endorphin plasma concentration
augmented the peripheral pain threshold to radiant
heat, similarly to our results, do not confirm
a significant effect of the β-endorphin level on the
angina threshold and workload during an exercise
test in patients with stable angina pectoris. The
different influence of β-endorphins on somatic and
cardiac pain perception was explained by the
specific effect of peripheral nociceptors, a distinct
central mechanism of somatic and cardiac
sensation perception in the thalamus, and
a different central and circulating opioid effect 
[14, 21]. The last explanation may elucidate
improvement only in 35% of subjects observed in
our study, although the higher plasma level of 
β-endorphin in patients who failed to respond to
the “omeprazole test” and in patients with greater
severity of angina symptoms before involvement
in the study is difficult to explain. One of the
potential explanations of these observations may
be a significantly greater hypertensive response to
exercise in non-responders than in responders at
the study beginning (systolic blood pressure: 174
±20 vs. 157 ±16, p = 0.004, and diastolic blood
pressure: 98 ±11 vs. 91 ±8, p = 0.04). Ring et al. [21]
suggested that hypertension appears to be
characterised by greater levels of β-endorphins in
the peripheral circulation. The second potential
explanation of higher opioid plasma levels in non-
responders might be higher anxiety level, secondary
to symptoms severity [14, 22]. Panic disorders are
frequent in patients with CAD [25]. On the other
hand, it is proven that pain causes anxiety and
panic disorders increase the intensity of pain, thus
demanding higher doses of analgesics, in our study
endogenous β-endorphins [26]. Unfortunately, we
did not measure anxiety level in our investigation.
Thirdly, it may also be supposed that failure of
symptoms improvement after treatment with
omeprazole resulted from a very low pain threshold
in “non-responders”. In this way, the greater 
β-endorphin plasma level in such patients would
be a compensatory reaction, although in our study
not sufficient to give pain relief.
The potential mechanism of increase in the 
β-endorphin plasma concentration after omeprazole
administration may only be supposed. The most
probable is acting via the stimulation of pituitary
Arch Med Sci 2, April / 2010 205206 Arch Med Sci 2, April / 2010
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opioid release, similar to ketoconazole [14].
Neuroendocrine activation associated with stress
or anxiety provoked by symptom severity or
myocardial ischaemia cannot be excluded [22],
although this hypothesis is not consistent with the
lower plasma level of this opioid both at the
beginning of the study and following the placebo
phase when symptoms severity was greater. An
increase in the β-endorphin level after therapy with
omeprazole may also be explained by the recently
proven anti-inflammatory action of proton pump
inhibitors in patients with GORD (a decrease 
in mucosal IL-8) [27]. It is known that the
administration of proton pump inhibitors
diminishes acute inflammatory cell infiltration in
oesophageal mucosa. The remaining chronic
inflammation dominated by T-lymphocytes is
associated with an increase in β-endorphin release
and a reduction in visceral pain perception [28]. This
effect, also observed in patients with chronic or
quiescent colitis, is explained by feedback neuro-
immune cross-talk between mucosal T-cells and the
enteric nervous system mediated via β-endorphin
[28, 29]. Moreover, because it is known that
omeprazole inhibits cytochrome P450 (CYP) 2C19,
its influence on β-endorphin clearance should also
be taken into consideration [30, 31].
Our investigation has some limitations. Firstly,
sample size was limited to 48 patients, although
other similar cross-over trials have involved even
fewer patients than our study [5, 6]. Our results,
similarly to the cited works, reached statistical
significance. On the other hand, together with the
relatively small subject sample size the risk of an
influence of confounding factors (e.g. pharmacology,
age, gender, diabetes mellitus) appears. However,
this bias was minimized by the cross-over study
design and the use of ANOVA with three repetitions
as a statistical method (each patient acted as his
or her own control), as well as by subgroup analysis.
All these methods decreased the role of sample size
and confounding factors, especially differences in
kind and dosage of medication. Secondly, in the
investigation design we did not provide a “washout
period”. This fact may be a cause of the relatively
high β-endorphin plasma level after 14 days of
placebo administration, in patients who were
randomized to taking omeprazole as the first drug.
However, the observed changes in β-endorphin
plasma level were similar irrespectively of the
sequence of treatment (first week omeprazole and
then placebo or the other way round). So, the lack
of “washout” seems to have no significant effect
on the obtained results. 
In conclusion, 14-day therapy with a double dose
of omeprazole significantly increases β-endorphin
plasma concentration in patients with CAD.
Circulating  β-endorphin does not seem to be
involved in the mechanism for the “omeprazole
test” outcome, although an individually different
effect on pain threshold cannot be excluded. 
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